OA10.05 An Open-Label, Multicenter, Phase II Single Arm Trial of Osimertinib in NSCLC Patients with Uncommon EGFR Mutation(KCSG-LU15-09)
2018
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
9
Citations
NaN
KQI